A recent study published in The New England Journal of Medicine found that sotatercept, utilized in high-risk patients with pulmonary arterial hypertension (PAH), was correlated with a significant reduction in serious clinical events, including a lower occurrence of lung transplantation, hospitalization due to worsening PAH, and death from any cause. Researchers concluded that sotatercept reduced the risk of major clinical outcomes in advanced PAH patients at high risk for death, when added to background therapy.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
